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CONNECTIVE TISSUE ACTIVATION 
XXVII. The Behavior of Skin Fibroblasts from Patients with Scleroderma 
A. CABRAL and C. W. CASTOR 
Four normal (NF) and 4 scleroderma skin fibro- 
blast (SF) strains were compared with respect to 1) basal 
14 C-gldcommine and '5S04-labeled glycosaminoglycan 
(GAG) synthesis, 2) responsiveness to autacdid media- 
tors, and 3) perfarmance following maximal stimula- 
tion. Under basal conditions, SF synthesized and secret- 
ed 2-3 times more radioactive hyaluronic acid than the 
NF (P < 0.001); molecular volume by gel chromatogra- 
phy was similar and suggested a high molecular weight 
ptoduct. SF were essentially as responsive to normal 
lymphoid and platelet factors as were NF. No consistent 
qualitative or quantitative differences in sulfated GAG 
synthesis were noted between the 2 groups of cells. 
Incubation df NF and SF with a false "core protein" 
such as p-nitrophenyl-PD-xyloside suggested that syn- 
thesis of the core protein was rate limiting; SF and NF 
were equally facile in S04-GAG chain synthesis in the 
presence of a pxyloside. SF appear to retain in vitro a 
partially activated State for many generations, at least 
with respect to hyaluronic acid synthesis. 
Scleroderma or progressive systemic sclerosis 
(PSS) is a multisystem disease characterized by prolif- 
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erative vascular lesions, chronic inflammatory infiltra- 
tions, and in late stages, excessive deposition of 
connective tissue in many organs (1,2). The skin of 
PSS patients is the most common site of involvement 
and the most common cause of complaint. Although 
the etiology remains obscure, it seems clear that 
abnormal accumulation of some components of the 
extracellular matrix is an important pathophysiologic 
feature. 
Recent studies have shown that involved 
scleroderma skin has an increased dry weight associat- 
ed with an increased collagen content (3) ,  increased 
amounts of type I procollagen in the deeper dermis and 
subcutaneous tissue (4), and abnormal distribution of 
fibronectin (5 ) .  The mechanisms of such abnormalities 
have been studied by using skin fibroblasts from 
affected individuals and measuring their capacity to 
synthesize some of these proteins in vitro. Thus, it is 
known that the scleroderma skin fibroblast (SF) cul- 
tures exhibit an exaggerated collagen synthesis rate 
when compared with normal skin fibroblasts (NF) (6- 
8). 
Data from several laboratories concerning gly- 
cosaminoglycan (GAG) synthesis in PSS have yielded 
conflicting results. In 1958, Denko and Stoughton (9) 
presented evidence indicating that sclerodermatous 
skin of 3 PSS patients had higher %O4 uptake than 
uninvolved skin. Later, Uitto et a1 showed that grossly 
unaffected skin from 9 scleroderma patients had twice 
the total GAG content found in 9 controls, mostly due 
to an increase in chondroitin 4/6 sulfate (10). In 
contrast, studies from 2 different laboratories (1  1,121 
have found increased GAG content in scleroderma 
skin to be primarily due to marked increase in derma- 
tan sulfate associated with either high or decreased 
Arthritis pad Rheumatism, Vol. 26, No. 11 (November 1983) 
CONNECTIVE TISSUE ACTIVATION 1363 
hyaluronic acid (HA) content. Unfortunately, none of 
these studies measured the cellularity or D N A  content 
of the specimens, and technical aspects of GAG frac- 
tionation schemes may explain the disagreement in 
results with respect to specific GAGs. I t  is also 
possible that the variable data result from different 
stages in the disease process. 
More recent reports of GAG synthesis profiles 
in the 7 PSS dermal cell strains reported thus far have 
furnished apparently different results (13,14). Bashey 
et  a1 (13) reported 3H-glucosamine incorporation into 
GAG by 4 N F  and 4 SF cultures. Although total 
uptake of labeled glucosamine and total secretion of 
3H-GAG appeared somewhat higher in confluent 
scleroderma fibroblast cultures, these authors con- 
cluded that "no differences were noted in 'H-gluco- 
samine incorporation or in GAG biosynthesis between 
normal and scleroderma cultured fibroblasts." Buck- 
ingham et a1 (14) found that dermal fibroblast cultures 
derived from the lower portions of biopsy samples 
from 3 patients with early PSS synthesized "increased 
amounts of all major glycosaminoglycans" when stud- 
ied with 3H-glucosamine. 
Previous studies from this laboratory identified 
small molecular weight proteins present in lymphoid 
tissue (IS) ,  platelets (16,17), and neutrophils (18) with 
the capacity to  elicit multiple metabolic responses 
from human connective tissue cells in vitro. These 
included increased formation of GAG, increased glu- 
cose uptake and lactate formation, increased D N A  
synthesis, enhanced prostaglandin production (partic- 
ularly the E series) (19), increased activity of H A  
synthetase (20), and induction of increased synthesis 
of plasminogen activator (21). Connective tissue acti- 
vation has been defined as the sum of these activities, 
and the stimulatory agents have been termed "connec- 
tive tissue activating peptides" (CTAPs). 
In view of the uncertainty concerning GAG 
synthesis by PSS fibroblasts, w e  undertook this study 
to  examine basal cellular performance, responsiveness 
to normal autacoid mediators, and performance under 
maximal stimulation, in an attempt to  enhance our  
understanding of the physiologic performance of "PSS 
fibroblasts" confronted with different regulatory set- 
tings. In the same experiments, we defined several 
superficial characteristics of proteoglycans (PGs) and 
hyaluronic acid synthesized in vitro by normal and 
PSS dermal fibroblasts. 
PATIENTS AND METHODS 
Skin fibroblast cultures were derived from 4 normal 
volunteers, and after informed consent, from the affected 
skin of 4 patients with an established diagnosis of progres- 
sive systemic sclerosis (Table 1). Details of culture methods 
have been reported previously (22). Briefly, NF and SF  were 
developed from explants and grown as monolayer cultures in 
medium CMRL 1066 (Gibco, Grand Island, NY), supple- 
mented with 10% fetal calf serum (FCS: Reheis Chemical 
Co., Kankakee, IL), 10% heat inactivated human serum 
(normal donors), L-glutamine (Sigma, St. Louis, MO), peni- 
cillin (Pfizer, New York, NY), streptomycin (Mzer), eryth- 
romycin (Dista Laboratories, Indianapolis, IN), 0.02M 
HEPES (Sigma), and sodium bicarbonate. Complete medi- 
um changes were carried out 3 times a week and trypsin 
(Worthington Biochemicals, Freehold, NJ) dispersal was 
performed as required for propagation or study. The cells 
used in this study had been transferred 3 to 11 times. 
Isotope incorporation studies. As previously de- 
scribed in detail (23). cells were plated in microtiter wells 
(Costar), 2.0 x lo4 cells per well, in assay medium consisting 
of 100 pl of Eagle's synthetic media (ESM; Gibco), supple- 
mented with 3% FCS, L-glutamine, antibiotics, HEPES, and 
Na2C03. After 20-24 hours incubation at 35-37°C in a 
humidified chamber to allow cell attachment and spreading, 
an additional 100 pl of assay media containing uniformly 
labeled D(U-'4C)-glucosamine-HC1, (Amersham Corp., Ar- 
lington Heights, IL; specific activity 254 mCi/ml), 0.5 pCi/ml 
medium, or 50-100 pCi/ml "SO4 (specific activity 20-40 
Cilmg; Arnersham Co.) was added. Test additives consisted 
of 20 pi of CTAP-Ib (180 pg/ml) from spleen, CTAP-P2 (160 
pg/ml), CTAP-111 (180 pglml) from platelets, p-nitrophenyl- 
PD-pyranoside (100 d m l )  (Sigma), or the appropriate 
vehicle. These microcultures (4 wells/group) were then incu- 
bated under the same conditions for an additional 40-48 
hours. 
Measurement of ''C-glucosamine or 35S04 incorpo- 
ration into GAG was quantitated as described (23). In brief, 
100-pl aliquots of media were spotted on Whatrnan 3 MM 
chromatography paper, and the GAG fixed to the paper by 
immersing it in a 0.1% solution of cetylpyridinium chloride 
(CPC; Sigma). Unincorporated label was removed by se- 
quential washes with 0. IN NaOH in the case of ''C-labeled 
media or with 0.1% CPC in 0.3M NaCl for "SO4-labeIed 
media. The remaining media was pooled separately by group 
and stored at -20°C. 
Long-term culture experiments. Using duplicate 
plates, 5 X lo4 cells/well were plated in 24-well plates 
(Costar), in 500 p1 of growth mediumlwell. After 20-24 hours 
incubation at 35-37"C, an additional 500 pI of growth medi- 
um containing 200 pCi/ml of uniformly labeled 35S04 was 
added to one of the plates; the same volume of cold medium 
was added to the duplicate plate and incubation was re- 
sumed. On day 3, 100 pl of labeled medium from each well 
was spotted on Whatman 3 MM chromatography paper and 
subjected to the CPC fixation-wash procedure described 
above. The remaining media was pooled separately by group 
and stored at -20°C. The cell sheet was rinsed 3 times with 
phosphate buffered saline (PBS) at room temperature, and 
the total protein content (24) and identification of GAGs 
were determined in the cell lysate. For this purpose, cells 
were lysed with 1.1 ml of either Lowry's Reagent C or 
Zwitterionic detergent (12 mg/ml) (Calbiochem-Behring 
Corp, San Diego, CA). 
Media in the duplicate plate was changed on days 3 
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Table 1. Clinical data: progressive systemic sclerosis (PSS) patients and normal controls 
~ 
Disease 
Site of Organ duration 




































Skin, lung, esophagus, 23 
Skin, esophagus, 1 









Skin, lung, esophagus, 6 
* V = volar; D = dorsum. 
and 6. On day 8,  100 pCi/ml of 35S04 was added to the 
cultures with a complete medium change, and the cultures 
were harvested on day 10 and processed as described above. 
All cultures were confluent by day 6-7. 
Enzymatic analysis of GAGs. Qualitative identifica- 
tion of GAGs was accomplished by incubating labeled media 
with hyaluronidase (ex. Streptornyces hyulurolyticus, Cal- 
biochem) in 0.15M sodium acetate pH 5, chondroitinase 
ABC, or AC (Miles Laboratories, Elkhart, IN) in 0.2M Tris 
pH 7.5 or the appropriate buffer for 3 hours at 37°C. The 
digested and control samples were subjected to the CPC 
fixation-wash procedure and GAG identity was determined 
on the basis of specific enzyme lability. 
Characterization of proteoglycans. Tissue culture 
flasks (25 cm2) were plated with 2 x lo6 normal or scleroder- 
ma fibroblasts and nourished with 5 ml of growth media. 
After 20-24 hours incubation at 3 7 T ,  the initial medium was 
removed, the cell sheet rinsed twice with sterile PBS. 5 ml of 
assay medium containing '%O4 (100 pCi/ml) was added, and 
incubation was resumed for another 40-48 hours. Medium 
was collected and dialyzed for 7 2  hours at 4°C against 200 
volumes of PBS with 2 changes over this period. The 
retentate was lyophilized, resuspended in PBS, and chroma- 
tographed over a calibrated 2.5 x 25 cm Sephacryl S-300 
column (Pharmacia Fine Chemicals, Piscataway , NJ). One 
hundred microliters of each 3-ml fraction was spotted on 
chromatography paper, and the eluted radiolabeled material 
was measured by liquid scintillation counting. The remain- 
der of the column fractions were lyophilized, hydrated to 
working volumes with PBS, and subjected to enzymatic 
analysis as described above. 
Characterization of HA molecular weight. N F  and S F  
(1.2 x lo6) were plated in 75 cm2 plastic flasks and supported 
with assay medium. After approximately 20 hours incuba- 
tion at 37°C to allow attachment and spreading of cells, 1 .O 
pCi/ml of ''C-glucosamine was introduced, and incubation 
resumed. After 40 hours incubation with labeled precursor, 
media were harvested and an aliquot from each sample was 
dialyzed overnight against approximately 200 volumes of 
0.02M acetate buffer pH 5 at 4°C. The retentate was centri- 
fuged at 30,OOOg, 4"C, and the precipitate, which contained 
I4C-HA, was resuspended to working volumes with 0.5M 
NaAc, pH 6.9. Samples of dialyzed and nondialyzed labeled 
medium were chromatographed on a calibrated Sepharose 
4B column (27 x 2.5 cm) (Pharmacia Fine Chemicals, 
Uppsala, Sweden) and eluted with 0.5M NaAc pH 6.9. Two 
hundred microliters of each 2-ml fraction were spotted on 
chromatography paper and the CPC precipitable material 
was determined by scintillation counting. The remainder of 
the void volume fractions were lyophilized, hydrated to 
working volumes with PBS, and the GAG was identified 
enzymatically. Immediately after the media were harvested. 
the cell mats were rinsed 3 times with PBS, lysed with 5 ml 
of Zwitterionic detergent for 2 hours at 37"C, and the 
qualitative identification of GAG was determined by specific 
enzyme lability of CPC precipitable material. 
Statistical analysis. Statistical analysis was performed 
using the Student-Fisher t-test. Bar graphs were constructed 
to display the mean * 1 standard deviation of the data. 
RESULTS 
Hyaluronic acid formation. Normal and PSS 
fibroblasts were incubated in the presence of I4C- 
glucosamine with and without the influence of three 
CTAP mediators; the results are depicted in Figure I .  
It is clear that under basal conditions, scleroderma 
skin fibroblasts synthesize and secrete 2- or 3-fold more 
''C-hyaluronic acid than the normal control fibroblasts 
(P < 0.001). In the mediator-treated cultures, very 
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NoCl CTAP-Ib CTAPIU CTAP-P, 
Figure 1. Stimulation of hyaluronic acid (HA) synthesis. The con- 
centrations of agonists used were: connective tissue activating 
160 pg/ml. All 3 mediators stimulated “C-HA synthesis compared 
with the appropriate (normal or scleroderma skin fibroblast) con- 
trols (NaCI-treated cultures). 
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Figure 2. Gel filtration on a Sepharose 4B column of labeled 
hyaluronic acid from skin culture media showed that the macromol- 
ecules eluted in the void volume (Vo). 
high concentrations were used in an attempt to pro- 
mote a maximal response. The platelet factors (CTAP- 
I11 and CTAP-P2) stimulated I4C-HA synthesis to 
similar absolute levels, while both types of fibroblasts 
were relatively resistant to CTAP-Ib from human 
spleen. Thus, it is clear that SF propagated in vitro 
retain the capacity to be “activated” by autacoid 
mediators to levels comparable with normal cultures. 
The molecular weights of 14C-HA secreted by 
normal and scleroderma skin fibroblasts were also 
compared. ‘‘C-glucosamine labeled HA was chroma- 
tographed on a Sepharose 4B column; results of a 
typical experiment are shown in Figure 2. As can be 
seen, normal and scleroderma I4C-HA eluted in the 
void volume of the calibrated column. We interpret the 
data to mean only that both N F  and SF synthesize 
large HA molecules, not that they necessarily have 
identical molecular weights. These secreted macro- 
molecules were entirely hydrolyzed by fungal hyal- 
uronidase. 
Synthesis of suifated GAG. Normal and sclero- 
derma skin fibroblast cultures were compared with 
regard to total synthesis and secretion of 35S-GAGs. 
As shown in Figure 3,  in short-term assays (i.e., 
approximately 72 hours) both N F  and SF incorporated 
and secreted variable amounts of CPC-precipitable 
”S-macromolecules with no clear-cut difference in 
total synthesis under nonstimulatory conditions. In 
v) 
%%I Norma I ( 4 )  
S c l e r o d e r m a ( 4 )  T I  
-Xyloside 
Figure 3. 35S-glycosaminoglycan (GAG) synthesis was modified by 
introduction of a pxyloside, leading to marked and similar increase 
in GAG chain synthesis in normal and scleroderma skin fibroblast 
cultures. 
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Table 2. 
fibroblast cultures* 
JSS04-glycosaminoglycan formation by normal and progressive systemic sclerosis (PSS) 
Short-term Long-term 
(3 days) (10 days) Cell 
source Media Cells Media Cells 
1 (normal) 7.14 f 0.35 2.80 2 0.14 3.73 + 0.23 3.37 f 0.03 
2 (normal) 7.58 f 0.33 2.58 2 0.07 5.64 + 0.36 4.13 f 0.24 
GA (PSS) 5.92 f 0.32 3.43 _C 0.54 4.73 2 0.08 3.07 + 0.54 
GG (PSS) 10.81 f 0.51 3.38 2 0.16 7.58 2 0.62 2.05 + 0.24 
IC (PSS) 6.71 f 0.64 2.75 2 0.29 4.96 + 0.25 3.30 f 0.50 
* Cultures were treated as described in the Patients and Methods section, and harvested at days 3 and 
10 after being exposed to )‘SO4 for the final 48 hours. Numbers represent 3SS04-glycosaminoglycan 
counts per minute x lo4 per mg cell protein, mean 2 SD of 6 cultures. 
3 (normal) 5.51 t 0.22 3.60 f 0.18 3.18 f 0.11 3.55 f 0.44 
contrast, when a pxyloside such as p-nitrophenyl-p 
D-xyloside was introduced into the cultures, higher, 
but similar, rates of carbohydrate chain biosynthesis 
were noted ( P  < 0.4), suggesting that this is not a rate 
limiting factor in these cultures. Aberrations in core 
protein synthesis or xylosyltransferase activity have 
not been ruled out. 
In view of these results, experiments were 
performed in which “short-term” cultures (72 hours) 
and “prolonged” cultures (240 hours) were compared 
with respect to the quantitative and qualitative aspects 
of 35S-GAG synthesis. Duplicate plates were nour- 
ished with regular growth medium to obtain maximal 
serum-dependent stimulation and cultures were termi- 
nated at either day 3 or 10, after having been exposed 
to 35S04 for the final 48 hours. The results of these 
experiments (Table 2) show clearly that under both 
short- and long-term assay conditions, no clear-cut 
quantitative or qualitative differences in synthesis of 
S-GAG were noted between the PSS and control cells 
( P  < O S ) ,  regardless of whether one examined youn- 
ger (less confluent) or older (denser) cultures. 
Radiolabeled macromolecules released into the 
culture media were subjected to hydrolysis by fungal 
hyaluronidase and chondroitinases ABC and AC. Ta- 
ble 3 summarizes the results of the analyses of labeled 
GAG isolated from N F  and SF cultures. Most of the 
14C-glucosamine labeled GAG was hydrolyzed by the 
fungal hyaluronidase, in agreement with a previous 
report (13). In contrast, when ”SO4 was used as a 
precursor, 60-70% was incorporated into chondroitin- 
ase AC-sensitive GAG and released into the culture 
medium; 20-25% of the incorporated radioactivity was 
found in cell-associated dermatan sulfate. It is interest- 
ing to note that overall, there were no qualitative 
differences in the labeled macromolecules synthesized 
by the PSS and control fibroblasts ( P  < 0.1) regardless 
of the isotopic precursor utilized and culture duration. 
As can be seen, approximately 30% of the incorporat- 
ed radiosulfate was not hydrolyzed by the chondroitin- 
ases; this may include heparan-sulfate as well as 
sulfated lipids and glycoproteins. 
Proteoglycan formation. Nonstimulated conflu- 
ent cultures of control and PSS fibroblasts were incu- 
bated with 35S04 for 40 hours and the labeled macro- 
molecules secreted into the media were subjected to 
gel filtration over Sephacryl S-300; the results are 
shown in Figure 4. In this experiment, scleroderma 
fibroblasts synthesized and secreted more 35S04-GAG 
than controls; these macromolecules eluted in the void 
Table 3. Qualitative comparison of glycosaminoglycan (GAG) synthesis in fibroblast cultures 
(percentage of total GAG hydrolyzed)* 
Media Cells 
GAG and enzyme Normal Scleroderma Normal Scleroderma Pt 
I4C-GAG + S. Hyaluronidase 76 f 9 79 f 7 71 f 21 75 2 25 NS 
”S-GAG + chondroitinase ACS 60 f 3 72 f 9 42 t 20 41 2 19 NS 
”S-GAG + chondroitinase ABCS 0 0 2 5 2  9 2 2 2  9 NS 
* Numbers represent mean percentage hydrolyses of total label f I SD. 
t NS = not significant. 
$ Results from short-term cultures and long-term cultures were found to be the same 
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Figure 4. Gel filtration of ”S-proteoglycan (PG) over a Sephacryl S- 
300 calumn Virtually all radiolabeled material appeared in the void 
volume (Vo), indicating that its size was M.75 x 10‘ daltons, a size 
clearly compatible with PG monomer and too large for glycosamino- 
glycan “chains ” 
volume of the column, suggesting a molecular weight 
of B0.75 x lo6 daltons. Enzymatic analysis showed 
that most of it was digestible by chondroitinase AC. 
Virtually no free GAG chain was detected. 
DISCUSSION 
In vitro culture of connective tissue cells has 
been useful in the study of human disorders such as 
heritable connective tissue diseases (25,26), pretibial 
myxedema (27), and rheumatoid arthritis (28) by per- 
mitting measurement of biosynthetic rates and/or re- 
sponse to hormones, mediators, and drugs. Fibro- 
blasts derived from affected scleroderma skin have 
been studied, and there is now convincing documenta- 
tion of overproduction of collagen and fibronectin by 
these cells growing in monolayer cultures (5-8). The 
present work extends these observations to include 
another component of the extracellular matrix, partic- 
ularly high molecular weight hyaluronic acid. Four 
scleroderma and 4 normal skin strains were studied 
with regard to their ability to synthesize and secrete 
GAG into the culture medium; when the 35S04 precur- 
sor was used, no consistent differences in synthesis 
were seen. This may reflect the assay conditions in 
these experiments or heterogeneity in the cell popula- 
tions with respect to sulfated GAG synthesis and/or 
differences in activity of clinical disease at the time of 
biopsy (Table 2). 
The experiments with p-nitrophenyl-P-D-xylo- 
side, which presumably acts as a “false core protein” 
by serving as an attachment site for carbohydrate 
chains, shed some light on this issue. When N F  and SF 
were incubated in the presence of a p-xyloside (Figure 
3), a similar rate of synthesis was noted, suggesting 
that sulfated carbohydrate chain formation was not a 
rate limiting factor in these cultures. Most of the 
radiosulfate-labeled material in the media and cell 
layer was chondroitin 4/6 sulfate. Dermatan sulfate 
was only found in association with the cell sheet. The 
present data showing sulfated GAG from normal skin 
fibroblasts to be in the form of proteoglycan monomer 
are in agreement with a previous report (29), a finding 
now extended to include synthesis of proteoglycan 
monomer by scleroderma skin fibroblast cultures. 
It appears that the skin fibroblasts from patients 
with PSS, under basal in vitro conditions, form 2-3 
times more hyaluronic acid than normal control fibro- 
blasts ( P  < 0.001). It is tempting to speculate that this 
quantitative metabolic peculiarity may underlie the 
edema often seen in the early “wet” phase of sclero- 
derma. 
Although abnormal accumulation of radiola- 
beled hyaluronate may result from increased synthesis 
and/or decreased rate of degradation, it is important to 
note that these studies most likely reflect the former, 
since the radiolabeled hyaluronic acid released into the 
media in a 48-hour incubation is a reflection of the de 
novo synthesis of this polymer; the plasma hyaluroni- 
dases are known to be inactive at neutral or alkaline 
pH. Further, it is known that the intracellular hyal- 
uronidase (also active at low pH) is present primarily 
in lysosomes, and the quantity of HA reaching this 
organelle in short-term experiments is unlikely to 
interfere with the present results. It is not possible, 
however, to completely rule out a role for decreased 
rate of breakdown. The chromatographic profile of the 
hyaluronic acid secreted by normal cells is in accor- 
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dance with the work of others ( 3 0 ) ;  the parallel da ta  
from PSS cultures should b e  interpreted within the  
limitations of the gel filtration method. 
Other  reports describe increased synthesis of 
H A  by cells isolated from human patients. It has been 
shown that fibroblasts derived from the skin of pa- 
tients with Marfan’s syndrome ( 2 5 ) ,  Hurler’s syn- 
drome (31), osteogenesis imperfecta ( 2 6 ) ,  and from 
rheumatoid synovial membrane (22 ,28)  accumulate 
excessive amounts of hyaluronate when compared 
with normal cells of similar origin. Several factors are 
known to influence the rate of H A  production by 
mammalian cells in vitro, including insulin, cortisol 
and Mg++ ( 3 2 ) ,  CTAPs,  prostaglandins and c A M P  
(19), bacterial endotoxins ( 3 3 ) ,  viral infection (34), and 
viral transformation ( 3 5 ) .  In addition, culture condi- 
tions such as temperature, p H ,  serum concentration, 
and  cell density are important ( 3 2 ) .  At least with 
cAMP and a few of the CTAPs. it appears that they 
exert their effect by increasing the  activity of the 
hyaluronic acid synthetase complex (20). Serum com- 
ponents, insulin, and cortisol are also said to regulate 
HA synthetase activity ( 3 2 ) .  Thus ,  it may be  useful t o  
study the HA synthetase activity of PSS connective 
tissue cells in attempting to  explain the present data. 
In the present study, we show that, with respect 
t o  HA and PG synthesis, the SF respond to lymphoid 
and platelet derived factors in a normal fashion; this 
suggests that the  enzymatic mechanisms known to  
mediate these metabolic responses are intact. The  
synthesis of H A  appears t o  be activated in vivo by 
cause(s) yet unknown which lead to the persistence of 
a hypermetabolic state similar to that described for 
rheumatoid synovial fibroblasts (22 ,28) .  
Suitable explanation(s) as to  why PSS fibro- 
blasts accumulate more connective tissue components 
when isolated from their in vivo environment must 
take into account the fact that  these cells manifest this 
“abnormal” behavior even after several generations in 
vitro. In the absence of strong evidence suggesting a 
viral or genetic defect in PSS (l) ,  the models of in vivo 
fibroblast selection (36)  and in vivo activation (22 ,28)  
are both compatible with the  existing data.  
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